Avid Bioservices Inc (CDMO)

[biopharm]

It seems Gilead is interested in PPHM ex-employees... here is another:

but first...this is just from Roche below, and talks of the recovery process of molecules and I think Avid Bioservices can attain purity levels of unseen proportions vs others, and may hold some clues in why/how Avid is/will advance fast.

Its one thing to be able to even have the ability to create a living cell bank and increase purity by 625% from that of the original, but when I read the below.... when I read the words "drug" I can only think of PS Targeting Mabs, because if I was to go through all this trouble I'd want to do it with a drug that has such a unique binding property, such a unique dual MOA (targets flipped PS and boosts the immune system ) and my oh my.... this individual started out in Tustin at Peregrine/Avid.

What other "drug" could they be referring to that they bring in a contractor out of school for such activities ?? maybe a contractor with a little PS Targeting Mab handling experience...hmmmmm

-------------------------------------------------------------

Hundreds of therapeutic monoclonal antibodies (mAbs) are currently in development, and many companies have multiple antibodies in their pipelines. Current methodology used in recovery processes for these molecules are reviewed here. Basic unit operations such as harvest, Protein A affinity chromatography and additional polishing steps are surveyed. Alternative processes such as flocculation, precipitation and membrane chromatography are discussed. We also cover platform approaches to purification methods development, use of high throughput screening methods, and offer a view on future developments in purification methodology as applied to mAbs.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958570/

-------------------------------------------------------

Kimberly Wang

Research Associate at Gilead Sciences
Oceanside, California
Biotechnology

Current
Gilead Sciences, University of California, San Diego

Previous

University of California, San Diego, Avid Bioservices, Peregrine Pharmaceuticals

Education
University of California, San Diego

157 connections


https://www.linkedin.com/in/kimberly-wang-0995b4b3

Experience

Research Associate (Contractor)
Gilead Sciences
July 2015 – Present (8 months)Oceanside, CA
*Potency Group under Analytical Operations in the Process Development department*
-Developing ligand-binding ELISA assays to confirm efficacy of drug
-Performing activity and fluorescence assays to compare drug potency under numerous conditions
-Conducting migration and invasion assays using IncuCyte technology
-Running Biacore experiments to determine ligand-binding ability of drug
-Culturing cells to make a working cell bank and for cell-based assays

Senior Design Project - Increasing the Specificity and Purity of Antibodies for Clinical Diagnostics
University of California, San Diego
October 2014 – Present (1 year 5 months)

*Worked in conjunction with Beckman Coulter to produce a more pure antibody test kit*
-Antibody test kit commonly used as preliminary screen for kidney malfunction
-Designed new experimental process to purify the antibody of interest
-Used affinity column chromatography as purification process
-Purity increased to 625% of the original

Undergraduate Researcher
University of California, San Diego
January 2013 – April 2015 (2 years 4 months)

*Cancer metabolism and pathway research*
-Expansion and culture of cancer cell lines (and some stem cells)
-Virus production and transfection
-Bacterial transformation and cloning
-PCR, qPCR, RT-PCR
-Metabolite extraction and derivatization
-Gel electrophoresis and Western blotting

Intern
Avid Bioservices
June 2014 – September 2014 (4 months)Tustin, CA

*Quality Assurance internship*
-Analyzed and organized individual client observation project
-Presented the project to upper management
-Worked on batch release
-Learned and observed GMP practices
-Examined the role of each part of a contract manufacturing organization

Intern
Peregrine Pharmaceuticals
June 2013 – September 2013 (4 months)Tustin, CA

*Preclinical Development internship*
-Maintained cell culture
-Developed and executed assays (focused on the MTS cell proliferation colorimetric assay)
-Performed flow cytometry in conjunction with a UCI lab
-Practiced experiment design and setup
-Presented findings for upper management

...
..
https://www.linkedin.com/in/kimberly-wang-0995b4b3

I think its all about PS Targeting and could we have a little tug of war going on between AstraZeneca and Gilead in their PI3K approach, which just may be completely PS Targeting and that is what Gilead is trying to confirm possibly when they say "ligand-binding ability of drug" and that drug is very likely a PS Targeting drug.

--------------------------------------------------------

Still interesting, is that Gilead files patent for a what looks like a PI3K PS Targeting approach... back in December of 2012 and all of a sudden we now see the AstraZeneca surprise news with Peregrine but notice how they (AZ) are also picking up Acerta Pharma that comes with a PI3K target. They both just may be PS Targeting....

-------------------------------------------------------

Phosphatidylinositol 3-kinase inhibitors

Publication number US9018221 B2
Publication type Grant
Application number US 14/137,978
Publication date Apr 28, 2015
Filing date Dec 20, 2013
Priority date Dec 21, 2012
Also published as CA2895782A1, US20140179673, US20150218154, WO2014100765A1
Inventors Jerry Evarts, Leena PATEL, Jennifer A. TREIBERG, Stephane Perreault, Arthur Yeung, J. Purvis II Lafe, Musong Kim, Less «
Original Assignee Gilead Calistoga, Llc

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117100403

AstraZeneca completes transaction for majority equity stake investment in Acerta Pharma

02 February 2016

..
..
Acerta is also developing ACP-319, a novel isoform selective inhibitor of phosphoinositide 3-kinase (PI3K) delta.
...
..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120260511